Investor Presentation H1 2023

111 Investor presentation First six months of 2023 Novo NordiskⓇ First human dose with cell therapy in collaboration with Heartseed and others achieved in Q1 2023 Utilise internal capabilities and disease understanding for stem cell development Internal capabilities GMP-grade production capability my Therapeutic areas Accelerate innovation through partnerships • Heartseed Parkinson's disease iPSC derived cardiomyocyte spheroids for direct injection into heart • Heart failure • FHD in February 2023 Academic collaborations Ethical stem cell practices IP positions on differentiation protocols Chronic heart failure LUND 2 first human dose projects upcoming UNIVERSITY Type 1 diabetes BioLamina REVOLUTIONIZING CELL CULTURE Dry age-related macular degeneration UCSF University of California San Francisco ● hESC derived dopaminergic progenitor neurons for placing into the brain Parkinson's disease • FHD in February 2023 • Novo Nordisk scientists embedded at UCSF lab Process development, manufacturing, QA/QC, facilities and operations at Fremont site GMP: Good manufacturing practice; IP: Intellectual property; iPSC: induced pluripotent stem cells; QA/QC: Combination of quality assurance with quality assurance and quality control; hESC: Human embryonic stem cell; FHD: First human dose

View entire presentation